Merck (MRK) announced that the National Medical Products Administration in China has approved Welireg for the treatment of adult patients with von Hippel-Lindau disease who require therapy for associated renal cell carcinoma, central nervous system hemangioblastomas or pancreatic neuroendocrine tumors, not requiring immediate surgery. Welireg is a first-in-class oral hypoxia-inducible factor-2 alpha inhibitor and is the first and only approved HIF-2alpha inhibitor in China. This approval is based on objective response rate and median duration of response results from the Phase 2 LITESPARK-004 trial and is the 17th approval of Welireg for these patients globally.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on MRK:
- Merck elects Surendralal Karsanbhai to board of directors
- U.S. FDA found asthma drug Singular, montelukast impacts the brain, Reuters says
- Pyxis Oncology announces preliminary PYX-201 data, collaboration with Merck
- Target reports downbeat Q3, Comcast plans cable TV spinoff: Morning Buzz
- Johnson & Johnson, Merck cutting jobs in China, Bloomberg reports
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
